Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Salvi

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
European Journal of Endocrinology|March 25, 2006
Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppressionMario Salvi, Guia Vannucchi, Irene Campi, et al.
The Journal of Clinical Endocrinology and Metabolism|December 16, 2014
Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled studyMario Salvi, Guia Vannucchi, Nicola Currò, et al.
Thyroid : Official Journal of the American Thyroid Association|November 25, 2020
Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' OrbitopathyGuia Vannucchi, Irene Campi, Danila Covelli, et al.
Thyroid : Official Journal of the American Thyroid Association|September 17, 2020
Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle DuctionsIrene Campi, Nicola Currò, Guia Vannucchi, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2012
Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapyGuia Vannucchi, Danila Covelli, Nicola Currò, et al.
European Journal of Endocrinology|January 16, 2007
Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open studyMario Salvi, Guia Vannucchi, Irene Campi, et al.
Thyroid : Official Journal of the American Thyroid Association|January 15, 2014
Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathyNicola Currò, Danila Covelli, Guia Vannucchi, et al.
Scientific Reports|June 1, 2018
Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathyLei Zhang, Giulia Masetti, Giuseppe Colucci, et al.
Frontiers in Endocrinology|February 11, 2022
Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' OrbitopathyIrene Campi, Guia Vannucchi, Ilaria Muller, et al.
Ophthalmology|February 13, 2013
A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathyIrene Campi, Guia M Vannucchi, Andrea M Minetti, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
European Journal of Endocrinology|March 25, 2006
Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppressionMario Salvi, Guia Vannucchi, Irene Campi, et al.
The Journal of Clinical Endocrinology and Metabolism|December 16, 2014
Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled studyMario Salvi, Guia Vannucchi, Nicola Currò, et al.
Thyroid : Official Journal of the American Thyroid Association|November 25, 2020
Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' OrbitopathyGuia Vannucchi, Irene Campi, Danila Covelli, et al.
Thyroid : Official Journal of the American Thyroid Association|September 17, 2020
Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle DuctionsIrene Campi, Nicola Currò, Guia Vannucchi, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2012
Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapyGuia Vannucchi, Danila Covelli, Nicola Currò, et al.
European Journal of Endocrinology|January 16, 2007
Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open studyMario Salvi, Guia Vannucchi, Irene Campi, et al.
Thyroid : Official Journal of the American Thyroid Association|January 15, 2014
Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathyNicola Currò, Danila Covelli, Guia Vannucchi, et al.
Scientific Reports|June 1, 2018
Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathyLei Zhang, Giulia Masetti, Giuseppe Colucci, et al.
Frontiers in Endocrinology|February 11, 2022
Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' OrbitopathyIrene Campi, Guia Vannucchi, Ilaria Muller, et al.
Ophthalmology|February 13, 2013
A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathyIrene Campi, Guia M Vannucchi, Andrea M Minetti, et al.
Pageof 6